A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer

被引：0
|
作者：
Chen, T. W-W
Yeh, D-C
Chao, T-Y
Lin, C-H
Chow, L. W-C
Hsieh, Y-Y
Huang, S-M
Cheng, A-L
Huang, C-S
Lu, Y-S
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Taichung Vet Gen Hosp, Taichung, Taiwan
[3] Taipei Med Univ, Div Hematol & Oncol, Shuang Ho Hosp, New Taipei, Taiwan
[4] UNIMED Med Inst, Comprehens Ctr Breast Dis, Wan Chai, Hong Kong, Peoples R China
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-14-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-23
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
    Mundi, P. S.
    Lee, S.
    Chi, D.
    Bhardwaj, A.
    Makower, D.
    Cigler, T.
    Crew, K. D.
    Hershman, D. L.
    Califano, A.
    Silva, J.
    Kalinsky, K. M.
    CANCER RESEARCH, 2017, 77
  • [22] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
  • [23] Phase I combination study of oral vinorelbine and oral cyclophosphamide in patients with metastatic breast cancer
    Ten Tije, AJ
    Lieverst, J
    Seynaeve, C
    Schornagel, J
    Feragotto, N
    Blanchot, G
    Ter Steeg, JD
    Laffranchi, B
    Verweij, J
    Schellens, JH
    Erasmus, MC
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S87 - S87
  • [24] Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer
    Saip, P.
    Eralp, Y.
    Ozkan, M.
    Karaca, H.
    Benekli, M.
    Cetin, B.
    Isikdogan, A.
    Kucukoner, M.
    Basaran, G.
    Sen, F.
    Un, O.
    Onur, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study
    R. Delva
    T. Pienkowski
    N. Tubiana
    U. Vanhoefer
    B. Longerey
    I. Douville
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 703 - 709
  • [26] Oral Vinorelbine in combination with capecitabine: phase I study in patients with metastatic breast cancer
    Nole, F.
    Catania, C.
    Sanna, G.
    Munzone, E.
    Corsetto, L.
    Longerey, B.
    Saindon, A.
    Brandely, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 134 - 134
  • [27] Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study
    Delva, R.
    Pienkowski, T.
    Tubiana, N.
    Vanhoefer, U.
    Longerey, B.
    Douville, I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 703 - 709
  • [28] Phase I/11 trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
    Kalinsky, K.
    Chi, D-C
    Lee, S.
    Adelson, K.
    Andreopoulou, E.
    Crew, K. D.
    Vahdat, L.
    Sparano, J. A.
    Hershman, D. L.
    Califano, A.
    Silva, J.
    Maurer, M. A.
    CANCER RESEARCH, 2013, 73
  • [29] Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
    Sung Hoon Sim
    In Hae Park
    Kyung Hae Jung
    Sung-Bae Kim
    Jin-Hee Ahn
    Kyung-Hun Lee
    Seock-Ah Im
    Young-Hyuck Im
    Yeon Hee Park
    Joohyuk Sohn
    Yu Jung Kim
    Suee Lee
    Hee-Jun Kim
    Yee Soo Chae
    Kyong Hwa Park
    Byung-Ho Nam
    Keun Seok Lee
    Jungsil Ro
    British Journal of Cancer, 2019, 121 : 985 - 990
  • [30] Phase II Study of a Triple Combination of Oral Vinorelbine, Capecitabine and Trastuzumab as First-line Treatment in HER2-positive Metastatic Breast Cancer
    Chan, Arlene
    Conte, Pier-Franco
    Petruzelka, Lubos
    Tubiana-Mathieu, Nicole
    Ganju, Vinod
    Llombart, Antonio
    Espie, Marc
    Majois, Francoise
    Gil, Miguel Gil
    Vaissiere, Nathalie
    Villanova, Gustavo
    ANTICANCER RESEARCH, 2013, 33 (06) : 2657 - 2664
12345